107 related articles for article (PubMed ID: 18619723)
21. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT.
Gleixner KV; Mayerhofer M; Sonneck K; Gruze A; Samorapoompichit P; Baumgartner C; Lee FY; Aichberger KJ; Manley PW; Fabbro D; Pickl WF; Sillaber C; Valent P
Haematologica; 2007 Nov; 92(11):1451-9. PubMed ID: 18024392
[TBL] [Abstract][Full Text] [Related]
22. The novel tyrosine kinase inhibitor EXEL-0862 induces apoptosis in human FIP1L1-PDGFR-alpha-expressing cells through caspase-3-mediated cleavage of Mcl-1.
Pan J; Quintás-Cardama A; Manshouri T; Giles FJ; Lamb P; Tefferi A; Cortes J; Kantarjian H; Verstovsek S
Leukemia; 2007 Jul; 21(7):1395-404. PubMed ID: 17495975
[TBL] [Abstract][Full Text] [Related]
23. Oncostatin M is a FIP1L1/PDGFRA-dependent mediator of cytokine production in chronic eosinophilic leukemia.
Hoermann G; Cerny-Reiterer S; Sadovnik I; Müllauer L; Bilban M; Gröger M; Horny HP; Reiter A; Schmitt-Graeff A; Mannhalter C; Valent P; Mayerhofer M
Allergy; 2013 Jun; 68(6):713-23. PubMed ID: 23621172
[TBL] [Abstract][Full Text] [Related]
24. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFRbeta and FIP1L1-PDGFRalpha in vitro and in vivo.
Stover EH; Chen J; Lee BH; Cools J; McDowell E; Adelsperger J; Cullen D; Coburn A; Moore SA; Okabe R; Fabbro D; Manley PW; Griffin JD; Gilliland DG
Blood; 2005 Nov; 106(9):3206-13. PubMed ID: 16030188
[TBL] [Abstract][Full Text] [Related]
25. [FIP1L1/PDGFRalpha fusion gene-negative chronic eosinophilic leukemia with t(5;12)(q31;p13): a case report and review of literatures].
Luo RM; Wu SL; Tong CR; Qiu JY; Wu P; Lu DP
Zhonghua Nei Ke Za Zhi; 2008 Nov; 47(11):919-22. PubMed ID: 19080234
[TBL] [Abstract][Full Text] [Related]
26. Differentiation of eosinophilic leukemia EoL-1 cells into eosinophils induced by histone deacetylase inhibitors.
Ishihara K; Takahashi A; Kaneko M; Sugeno H; Hirasawa N; Hong J; Zee O; Ohuchi K
Life Sci; 2007 Mar; 80(13):1213-20. PubMed ID: 17258775
[TBL] [Abstract][Full Text] [Related]
27. FIP1L1-PDGFRalpha imposes eosinophil lineage commitment on hematopoietic stem/progenitor cells.
Fukushima K; Matsumura I; Ezoe S; Tokunaga M; Yasumi M; Satoh Y; Shibayama H; Tanaka H; Iwama A; Kanakura Y
J Biol Chem; 2009 Mar; 284(12):7719-32. PubMed ID: 19147501
[TBL] [Abstract][Full Text] [Related]
28. Synergistic antiproliferative effects of KIT tyrosine kinase inhibitors on neoplastic canine mast cells.
Gleixner KV; Rebuzzi L; Mayerhofer M; Gruze A; Hadzijusufovic E; Sonneck K; Vales A; Kneidinger M; Samorapoompichit P; Thaiwong T; Pickl WF; Yuzbasiyan-Gurkan V; Sillaber C; Willmann M; Valent P
Exp Hematol; 2007 Oct; 35(10):1510-21. PubMed ID: 17681669
[TBL] [Abstract][Full Text] [Related]
29. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
[TBL] [Abstract][Full Text] [Related]
30. The roles of MCP-1 and protein kinase C delta activation in human eosinophilic leukemia EoL-1 cells.
Lee JS; Yang EJ; Kim IS
Cytokine; 2009 Dec; 48(3):186-95. PubMed ID: 19664934
[TBL] [Abstract][Full Text] [Related]
31. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
32. Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia.
Wang Q; Liu F; Qi S; Qi Z; Yan XE; Wang B; Wang A; Wang W; Chen C; Liu X; Jiang Z; Hu Z; Wang L; Wang W; Ren T; Zhang S; Yun CH; Liu Q; Liu J
Eur J Med Chem; 2018 Apr; 150():366-384. PubMed ID: 29544149
[TBL] [Abstract][Full Text] [Related]
33. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival.
Shor AC; Keschman EA; Lee FY; Muro-Cacho C; Letson GD; Trent JC; Pledger WJ; Jove R
Cancer Res; 2007 Mar; 67(6):2800-8. PubMed ID: 17363602
[TBL] [Abstract][Full Text] [Related]
34. Dasatinib (BMS-354825) selectively induces apoptosis in lung cancer cells dependent on epidermal growth factor receptor signaling for survival.
Song L; Morris M; Bagui T; Lee FY; Jove R; Haura EB
Cancer Res; 2006 Jun; 66(11):5542-8. PubMed ID: 16740687
[TBL] [Abstract][Full Text] [Related]
35. Dasatinib exerts an immunosuppressive effect on CD8+ T cells specific for viral and leukemia antigens.
Fei F; Yu Y; Schmitt A; Rojewski MT; Chen B; Greiner J; Götz M; Guillaume P; Döhner H; Bunjes D; Schmitt M
Exp Hematol; 2008 Oct; 36(10):1297-308. PubMed ID: 18619726
[TBL] [Abstract][Full Text] [Related]
36. A case of FIP1L1-PDGFRA-positive chronic eosinophilic leukemia with a rare FIP1L1 breakpoint.
Lambert F; Heimann P; Herens C; Chariot A; Bours V
J Mol Diagn; 2007 Jul; 9(3):414-9. PubMed ID: 17591942
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
38. Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene.
Nishioka C; Ikezoe T; Yang J; Yokoyama A
Leukemia; 2010 Sep; 24(9):1631-40. PubMed ID: 20596030
[TBL] [Abstract][Full Text] [Related]
39. Cotreatment with vorinostat (suberoylanilide hydroxamic acid) enhances activity of dasatinib (BMS-354825) against imatinib mesylate-sensitive or imatinib mesylate-resistant chronic myelogenous leukemia cells.
Fiskus W; Pranpat M; Balasis M; Bali P; Estrella V; Kumaraswamy S; Rao R; Rocha K; Herger B; Lee F; Richon V; Bhalla K
Clin Cancer Res; 2006 Oct; 12(19):5869-78. PubMed ID: 17020995
[TBL] [Abstract][Full Text] [Related]
40. PKC potentiates tyrosine kinase inhibitors STI571 and dasatinib cytotoxic effect.
Tobío A; Alfonso A; Botana LM
Anticancer Res; 2014 Jul; 34(7):3347-56. PubMed ID: 24982339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]